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SplenectomyWe recently reported that infection of rats with the neurodegenerative disease-causing retrovirus PVC-211
MuLV results in elevated levels of the chemokine MIP-1α followed by the accumulation of activated microglia
in the brain. To investigate the importance of MIP-1α in recruitment of microglia to the brain, we treated rats
with MIP-1α antibodies before and after PVC-211 MuLV infection. This caused a delay in the development of
paralysis which was associated with a decrease in activated microglia without affecting virus expression. To
determine the source of activated microglia, rats were splenectomized 4 days after virus infection.
Splenectomized rats showed a delay in disease development that was associated with decreased numbers
of activated microglia without affecting virus expression. Together, these results suggest that MIP-1α is
directly involved in the neurodegeneration induced in rats by PVC-211 MuLV by recruiting macrophages/
microglia from the periphery into regions of the brain that eventually become diseased.tion, Building 567, Room 152,
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PVC-211 murine leukemia virus (MuLV) induces a rapid, age-
dependent spongiform neurodegenerative disease in rodents, result-
ing in paralysis (Kai and Furuta, 1984; Masuda et al., 1992). The
primary target of PVC-211 MuLV infection within the central nervous
system (CNS) is the brain capillary endothelial cell (BCEC) as shown
by both in vivo (Hoffman et al., 1992) and in vitro (Jinno-Oue et al.,
2001) experiments, suggesting that neurodegeneration caused by
PVC-211 MuLV is an indirect result of virus infection of blood vessels
within the CNS. Our recent data showed that brain vessels were
altered and microglia were activated following virus infection, and
that depletion of macrophages/microglia by clodronate-containing
liposomes signiﬁcantly blocked PVC-211 MuLV-induced neurodegen-
eration (Li et al., 2009). This suggests thatmicroglia, which can secrete
many cytokines/chemokines involved in neurodegeneration (Block et
al., 2007; Langmann, 2007), are the major cells contributing to the
neuropathogenesis induced by PVC-211 MuLV. We further showed
that the chemokine MIP-1α is elevated in both serum and brain
tissues of rats infected with PVC-211 MuLV (Li et al., 2009). MIP-1α
can act as a leukocyte chemoattractant (Menten et al., 2002) and
elevated levels of this chemokine play a role in a number ofneurodegenerative diseases (Balashov et al., 1999; Man et al., 2007;
Montanheiro et al., 2007; Reale et al., 2009; Tripathy et al., 2007; Wu
and Proia, 2004). However, it is unclear whether MIP-1α, by virtue of
its ability to attract macrophages/microglia, is directly involved in the
neurodegeneration caused by PVC-211 MuLV. It is also not known
whether the activated microglia found in the regions of the brain of
virus-infected rats that eventually become diseased are recruited
from residentmicroglia in the brain or from a peripheral organ such as
the spleen, a major source of macrophages/microglia.
In this study, we determined the effects on the course of PVC-211
MuLV-induced disease of treatment with antibodies to MIP-1α, which
reduced serum levels of the chemokine, as well as splenectomy, which
removed a major source of peripheral macrophages/microglia
available for recruitment by MIP-1α. Our data indicate that both
treatments decreased the number of activated microglia in the brains
of virus-infected rats without altering virus expression, leading to a
signiﬁcant delay in the development of neurodegeneration.Results
Anti-MIP-1α treatment delays PVC-211 MuLV-induced paralysis
Our previous data showed that increased expression of the
chemokine MIP-1α is associated with neurodegeneration induced
by PVC-211 MuLV (Li et al., 2009). In order to further understand the
importance of MIP-1α in the disease, we treated PVC-211 MuLV-
Fig. 1. Treatment of rats with neutralizing antibodies to MIP-1α delays spongiform
neurodegeneration and paralysis induced by PVC-211 MuLV but does not alter viral
replication. PVC-211 MuLV-infected rats were treated with anti-MIP-1α antibodies
beginning on the day prior to virus injection and continuing for 8 more injections
until 17 days post virus injection. Control PVC-211 MuLV-infected rats were treated
with non-immune serum or water. A total of 19 anti-MIP-1α-treated rats and 18
control rats from 4 different experiments were followed. A. Percentage of PVC-211
MuLV-infected rats with complete paralysis at various time points after virus
injection. ▲: PVC-211 MuLV-infected rats given anti-MIP-1α antibodies and ○: PVC-
211 MuLV-infected control rats. B. PVC-211 MuLV gp70 envelope expression in the
spleen, brainstem and serum from anti-MIP-1α-treated, control PVC-211 MuLV-
infected or uninfected rats at 24 dpi or at the end of the observation period (40 dpi)
(asterisk). β-actin was used as a loading control. The amount of MuLV gp70 was
quantitated in relationship to the loading control and is represented as a gp70/actin
ratio at the bottom of each lane.
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starting at birth (1 day prior to virus injection) and continuing for a total
of 9 injections, ending at 17 dpi (see Materials and methods). The dose
was adjusted for the age of the rat. As shown in Fig. 1, the paralysis
phenotype was markedly delayed in the PVC-211 MuLV-infected
rats that had been treated with anti-MIP-1α antibodies compared to
PVC-211 MuLV-infected control rats. At 26 days post virus injection,
only 16% (3/19) of the infected rats treatedwith anti-MIP-1α antibodies
became paralyzed, and the brains of these rats showed markedly less
spongiform neurodegeneration (data not shown) than control rats 44%
(8/18) of which were paralyzed by 26 dpi. At 32 days post virus
injection (and over 2 weeks after the last antibody injection), only 21%
(4/19) of rats treated with anti-MIP-1α antibodies showed complete
paralysis in contrast to 78% (14/18) of control rats. However, by day 40
post virus injection, 67% (10/15) of anti-MIP-1α-treated rats became
paralyzed. These data suggest that MIP-1α plays a causal role in the
neurodegeneration and paralysis induced by PVC-211 MuLV.
To exclude that the delay in the development of virus-induced
neurodegeneration after treatment with anti-MIP-1α antibodies was
caused by a decrease in the level of virus infection, we carried out
western blotting analysis to determine the levels of envelope protein
(gp70) of PVC-211 MuLV. As shown in Fig. 1B, similar amounts of viral
gp70 were detected in the spleen, brainstem and serum of PVC-211
MuLV-infected control rats and those treated with anti-MIP-1α
antibodies, indicating comparable viral load in treated and control rats.
PVC-211 MuLV-infected rats treated with anti-MIP-1α show decreased
levels of MIP-1α in the serum and fewer activated microglia in the brain
In order to conﬁrm that the anti-MIP-1α antibodies were
neutralizing MIP-1α in the virus-infected rats, we carried out a
speciﬁc immunoassay to detect the expression of MIP-1α in the
serum. As shown in Fig. 2A, PVC-211 MuLV-infected control rats
showed high levels of MIP-1α at 14 dpi, as previously reported (Li
et al., 2009). In contrast, the virus-infected rats given anti-MIP-1α
antibody showed signiﬁcantly (Pb0.05) less MIP-1α at 14 dpi,
indicating that the antibody was effective in neutralizing MIP-1α.
To determine whether activation of microglia is inﬂuenced by
administration of anti-MIP-1α antibody, immunostaining of brain
tissue with ED1 monoclonal antibody, which detects activated
microglia, was performed. At 21 dpi, less ED1 staining was found in
both the brainstem (Fig. 2B) and the cerebellum (data not shown) of
virus-infected rats treated with anti-MIP-1α antibody as compared
with controls, suggesting that lower amounts of MIP-1α delayed the
recruitment of activated microglia to the brain.
Splenectomy delays the paralysis phenotype in PVC-211 MuLV-infected
rats without decreasing virus infection
The source of activated microglia in the region of the brain that
becomes diseased can be from resident microglia that are recruited by
MIP-1α to those regions and from macrophages/microglia in the
periphery that are recruited by MIP-1α into the brain. Since the spleen
is one of the major peripheral sources of macrophages/microglia
available for recruitment by chemokines to the brain, we tested the
effect of removing the spleenon the development of neurodegeneration
induced by PVC-211 MuLV. Splenectomies were performed at 4 days of
age (2 days after virus injection). As shown in Fig. 3A, splenectomized
rats showed a marked delay in the development of neurodegeneration
and paralysis compared with control rats. By 26 days post-infection,
only 19% (4/21) of the splenectomized, virus-infected rats had become
paralyzed, while 73% (8/11) of the non-splenectomized, virus-infected
rats became paralyzed. By 40 days after infection, 67% (14/21) of the
splenectomized, PVC-211 MuLV-infected rats had become paralyzed,
perhaps reﬂecting the recruitment of macrophages/microglia from
other peripheral organs such as the bone marrow.Since the spleen is an organ where the virus has been shown to
replicate and removing this organ might decrease viral load, we
carried out western blot analysis to determine the level of PVC-211
MuLV envelope protein (gp70) in the brain. Splenectomy did not
signiﬁcantly decrease the level of MuLV gp70 in the brain at 24 dpi
(Fig. 3B) or 14 dpi (data not shown) and actually led to an increase in
expression in the bone marrow (Fig. 3B) compared with non-
splenectomized rats, allowing us to exclude the possibility that the
delay in disease after splenectomy was the result of lower viral titers
in the rats. The increased expression of MuLV gp70 in the bone
marrow of PVC-211 MuLV-infected splenectomized rats may result
from a high rate of proliferation in the bone marrow to compensate
for cells removed by splenectomy.
Increased MIP-1α levels and fewer activated microglia were found in
PVC-211 MuLV-infected, splenectomized rats compared with controls
To determine if the delayed paralysis phenotype found in
splenectomized rats was associated with a change in the levels of
MIP-1α, which we showed plays a role in neurodegeneration, we
carried out a speciﬁc immunoassay to detect MIP-1α in the serum of
splenectomized and control rats at various times after injection of
PVC-211 MuLV. As shown in Fig. 4A, MIP-1α levels in the serum of
PVC-211 MuLV-infected control rats were increased at 14 dpi, as
previously shown (Li et al., 2009). Interestingly, MIP-1α levels at
Fig. 2. PVC-211MuLV-infected rats treated with anti-MIP-1α antibodies show decreased levels of MIP-1α in the serum and fewer activatedmicroglia in the brain. A: Protein levels of
MIP-1α were detected by a speciﬁc immunoassay using serum from PVC-211 MuLV-infected rats collected at different time points after virus injection. Gray bars: rats given anti-
MIP-1α and black bars: control rats. Data represent means±SEM. Pb0.05 at 14 dpi and PN0.05 at 7 and 21 dpi. B: Activated microglia (upper panels) were detected at 21 dpi in
frozen sections of brainstem from PVC-211 MuLV-infected rats by immunoﬂuorescent (IF) staining with ED1 antibody (indicated by green color). Left: Control PVC-211 MuLV-
infected rats and middle and right: PVC-211 MuLV-infected rats treated with anti-MIP-1α antibodies. 20×. Comparison of the average number of activated microglia (as determined
by counting the number of ED1 antibody-positive cells per 20× ﬁeld) in the brainstem of 3 control rats and 3 anti-MIP-1α antibody-treated rats is shown at the bottom. Equivalent
numbers of cells (as determined by DAPI staining; not shown) were examined in each case.
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than those in the control rats (Pb0.05), most likely representing a
compensatory response to the loss of macrophages/monocytes
resulting from the spleen removal. However, analysis of the blood of
splenectomized and control rats at 4, 11 and 18 days after splenec-
tomy revealed no signiﬁcant differences in their leukocyte or red
blood cell counts (data not shown).
To determine whether splenectomy delayed microglia activation in
the brain, we performed immunostaining with ED1 antibody. As
shown in Fig. 4B, considerably fewer activated microglia were detected
at 21 dpi in the PVC-211 MuLV-infected rats after splenectomy.
Discussion
Previous studies have indicated that the neuropathogenesis
induced in rats by PVC-211 MuLV is the indirect result of virus
replication in brain capillary endothelial cells (Hoffman et al., 1992;
Masuda et al., 1992). We recently demonstrated that PVC-211 MuLV
infection of BCEC results in the production of the vascular permeabil-
ity factor VEGF and speculated that this is responsible for the vascularchanges seen in the brains of the virus-infected rats, leading to
activation of microglia in response to the vascular damage (Li et al.,
2009). The importance of microglia activation was shown by
depleting macrophages/microglia from rats before virus infection,
which caused a signiﬁcant reduction in the development of
neurodegeneration (Li et al., 2009). We also demonstrated that the
chemokine MIP-1α is speciﬁcally elevated in the brains and serum of
rats infected with PVC-211 MuLV and that this precedes the
accumulation of activated microglia in the diseased areas of the
brain (Li et al., 2009). In this study, we carried out experiments to
determine the importance of MIP-1α in activation of microglia and
development of neurological disease as well as experiments to
determine the source of the microglia recruited into diseased areas
of the brain by MIP-1α. Our studies indicate that blocking MIP-1α
markedly reduces microglia activation and delays the development of
paralysis in PVC-211 MuLV-infected rats, supporting a causal role for
MIP-1α in our virus-induced neurodegenerative disease. Our studies
further demonstrate that removing the spleen 2 days after infection of
rats with PVC-211 MuLV also reduces microglia activation and clearly
delays the development of paralysis, indicating that the spleen is an
Fig. 3. Splenectomy causes a delay in the paralysis phenotype of PVC-211 MuLV-
infected rats without decreasing virus replication. PVC-211 MuLV-infected rats were
splenectomized at 4 days of age. A total of 21 splenectomized rats and 11 PVC-211
MuLV-infected control rats from 2 different experiments were followed. A. Percentage
of PVC-211 MuLV-infected rats with complete paralysis at various time points after
virus injection. ▲: splenectomized PVC-211 MuLV-infected rats and ○: non-
splenectomized PVC-211 MuLV-infected rats. B. PVC-211 MuLV gp70 expression at
24 dpi in bone marrow and cerebellum from PVC-211 MuLV-infected rats with or
without splenectomy. The amount of MuLV gp70 was determined by Western blot
using anti-MuLV gp70 antiserum. β-actin was used as a loading control. The amount of
MuLV gp70 was quantitated in relationship to the loading control and is represented as
relative MuLV gp70 expression (gp70/actin) in the bar graph. Black bars: control rats
and gray bars: splenectomized rats. Data represent means±SEM.
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areas of the brains of the virus-infected rats. Taken together, our data
further supports the crucial role of activated microglia in the
neurodegenerative disease induced by PVC-211 MuLV.
MIP-1α is a CC-type chemokine that is a strong chemoattractant for
monocytes (Davatelis et al., 1988). MIP-1α plays a beneﬁcial role in
wound repair (DiPietro et al., 1998), but its overproduction has been
associated with neurodegenerative diseases in mice and humans
(Balashov et al., 1999; Man et al., 2007; Montanheiro et al., 2007;
Reale et al., 2009; Tripathy et al., 2007; Wu and Proia, 2004). In our
model,wepropose thatMIP-1α recruits largenumbers ofmacrophages/
microglia to the brain and that the activated microglia not only release
MIP-1α to recruit more microglia but also release other factors [e.g.
nitric oxide, reactive oxygen species and glutamate (Langmann, 2007)]
that can cause neuronal damage, leading to paralysis. Neutralization of
MIP-1α stops recruitment of macrophages/microglia to the brain,
essentially preventing the accumulation of sufﬁcient activatedmicroglia
to cause neurodegeneration. Although treatment of rats with anti-MIP-1α antibodies signiﬁcantly delayed the development of neurological
disease induced by PVC-211 MuLV, it did not prevent it. Up to day 32
after virus injection and over two weeks after stopping treatment with
MIP-1α neutralizing antibody, only 21% of the treated rats became
paralyzed, in contrast to 78% of the control rats. The fact that a few
treated rats became paralyzed during this time period may be due to
variations from rat to rat in the level of reduction of MIP-1α. After day
32, more of the MIP-1α antibody-treated rats gradually became
paralyzed, reaching 67% by day 40. This most likely reﬂects the
decreasing effects of the MIP-1α antibody treatment, which was
stopped on day 17 post virus injection.
Our data also shed some light on the source of the activated
microglia in the diseased areas of the brains of PVC-211 MuLV-
infected rats. Activatedmicroglia can come from two sources: resident
brain microglia or macrophages/microglia from peripheral tissues
such as the spleen or bone marrow. The spleen, which is a major
resource of macrophages/microglia, can respond to injury of the brain
by producing elevated levels of circulating cytokines (Dimagl et al.,
1999; Offner et al., 2006). Subsequently, macrophages/microglia
stored in the spleen are released into the bloodstream, from which
they inﬁltrate the brain and promote a secondary response that
enhances neurodegeneration (Ajmo et al., 2008). This major source of
macrophages/microglia is removed upon splenectomy. Different
neurological disease models have implicated either resident brain
microglia or peripheral macrophages/microglia recruited to the brain
in disease. In the rat middle cerebral artery occlusion (MCAO) model
of stroke, several groups have shown that the majority of the
macrophages in the neurodegenerating regions of the brain are
resident microglia (Denker et al., 2007; Schilling et al., 2003).
However, in another study using a rat MCAO model of neurodegen-
eration, the spleen was shown to play a signiﬁcant role in
neurodegeneration, indicating that inﬁltrating monocytes/macro-
phages from spleen were important (Ajmo et al., 2008). Also, in the
murine model for Sandhoff disease, a lysosomal storage disease,
researchers demonstrated that macrophages were recruited via MIP-
1α from the periphery into the CNS and implicated this in the
pathogenesis of the disease (Wu and Proia, 2004). In our model of
neurodegeneration, the results of splenectomy on PVC-211 MuLV-
induced neurodegenerative disease have provided evidence that
macrophages/microglia from the periphery, such as the spleen, but
not local resident microglia, may be the main source of the activated
microglia in the brain. Although splenectomy delayed the develop-
ment of paralysis after PVC-211 MuLV infection, it did not prevent it.
This is most likely due to a compensatory response of the rat to the
splenectomy, which would be to produce more macrophages to
replace the loss. In the splenectomized PVC-211 MuLV-infected rats,
we observed an increase in the level of MIP-1α after splenectomy, and
this may result in the production of more macrophages in other
organs, eventually creating another large peripheral pool of cells
which can be recruited by MIP-1α to the brain to cause paralysis.
In summary, our studies of PVC-211 MuLV-induced neurodegen-
eration demonstrate that the chemokine MIP-1α and splenic macro-
phages are important for microglia activation in the brain and the
development of paralysis in virus-infected rats. These studies suggest
that human neurodegenerative diseases associated with elevated
cytokines/chemokines and microglial activation, such as Alzheimer's
disease, Parkinson's disease and multiple sclerosis (Block et al., 2007),
may beneﬁt by targeting cytokines/chemokines, and perhaps their
receptors, as well as depleting peripheral sources of microglia.
Materials and methods
Virus and animals
PVC-211 MuLV was grown in Rat-1 or NIH 3T3 ﬁbroblasts in
Dulbecco's minimal essential medium plus 10% fetal calf serum, as
Fig. 4. Splenectomized PVC-211MuLV-infected rats show increased levels of MIP-1α in the serum and fewer activatedmicroglia in the brain. A: The protein levels ofMIP-1αwere
detected by a speciﬁc immunoassay using serum from PVC-211 MuLV-infected rats collected at different time points after virus injection. Gray bars: splenectomized rats and
black bars: control rats. Data representmeans±SEM. Pb0.05 at 14 dpi and PN0.05 at 9 and 24 dpi. B: Activatedmicroglia (upper panels)were detected at 21 dpi in frozen sections
of the brainstems of non-splenectomized (left panel) or splenectomized (right and middle panel) PVC-211 MuLV-infected rats by immunoﬂuorescent (IF) staining with ED1
antibody (indicated by green color). 20×. Comparison of the average number of activatedmicroglia (as determined by counting the number of ED1 antibody-positive cells per 20×
ﬁeld) in the brainstem of 3 control rats and 3 splenectomized rats is shown at the bottom. Equivalent numbers of cells (as determined by DAPI staining; not shown) were
examined in each case.
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collected 24 h after incubation of cells with fresh medium and stored
at −80 °C until use. Pregnant Fisher 344 (F344) rats were obtained
from the Small Animal Facility in NCI-Frederick. Two-day-old F344
rats were inoculated intracranially (i.c.) with 0.05–0.075 ml of
supernatant from virus-producing cells or with medium.Antibody administration
The administration of rabbit anti-rat MIP-1α antibody (PeproTech
Inc., Rocky Hill, NJ; Cat. # 500-P77) was started at birth [1 day before
virus injection (−1 dpi)] and continued on days 0, 3, 5, 7, 10, 12, 14
and 17 dpi. Three different doses were administered i.c. depending on
the age of the rats: 0–7 days of age (40 ng), 7–14 days of age (80 ng)and 14–19 days of age (100 ng). The amount of anti-MIP-1α
administered to rats was based on the concentration of MIP-1α
found in serum of PVC-211MuLV-infected rats (Li et al., 2009) and the
neutralization concentration provided by the manufacturer. Control
animals were injected with an equal amount of either normal rabbit
serum or water. Since neither control treatment had an effect on the
course of disease, the data was pooled.Immunoﬂuorescence
For immunostaining to detect ED1-positive cells, frozen sections
were ﬁxed in 50% acetone and 50%methanol at−20 °C for 30 min and
then permeabilized in 0.3% Triton X-100/PBS for 10 min. After
incubation in 5% milk in PBS for 1 h at RT, the slides were incubated
203X. Li et al. / Virology 409 (2011) 198–203overnight at 4 °C with ED1 monoclonal antibody (1:50, MCA341GA;
Serotec, Raleigh, NC). The next morning, the slides were washed with
PBS and then incubated with goat anti-mouse IgG coupled to Alexa
Fluor 488 (Invitrogen, Carlsbad, CA) for ED1 detection. Coverslips
were applied to slides with Pro-Long Gold antifade reagent and DAPI
(P36931; Invitrogen).
Measurement of MIP-1α in serum
The level ofMIP-1α in serumwas determined as previously described
(Li et al., 2009) using a CCL3 immunoassay kit (Cat. # MMA00; R&D
Systems, Minneapolis, MN) according to the manufacturer's directions.
Western blotting
Tissues were homogenized in lysis buffer (1% Triton X-100, 0.5%
sodium deoxycholate, and 0.1% sodium dodecyl sulfate in PBS) and
then resuspended in SDS-PAGE sample buffer (BioRad Laboratories,
Hercules, CA) containing a reducing agent. Proteins were separated by
electrophoresis on an 8% Tris–glycine gel (Invitrogen) and then
transferred to a nitrocellulose membrane (Invitrogen). The mem-
brane was then incubated with anti-RLV gp70 serum as previously
described (Jinno-Oue et al., 2003). Bound antibodywas detected using
peroxidase-labeled secondary antibody and the enhanced chemilu-
minescence system (GE Healthcare, Buckinghamshire, UK). Quanti-
tation of signals after autoradiography was performed by
densitometry utilizing NIH-Image software.
Splenectomies
On day 4 after birth, spleenswere removed as previously described
(Gray et al., 1985). Brieﬂy, rats were anaesthetized using isoﬂurane,
and a small incision wasmade just below the thoracic area. The spleen
was raised, the vessels between the spleen and pancreas were cut
using cauterization, and the spleen was removed. The peritoneal wall
was closed with 6–0 dexon and the skin was glued together with
tissue adhesive. Sham operated control animals were treated the
same way except that the spleen was not removed. Sham splenec-
tomy did not delay the onset of paralysis in infected rats (data not
shown). Therefore, non-splenectomized PVC-211 MuLV-infected rats
were used as controls for the splenectomy studies.
Statistical analysis
Student's t-test was employed and P values less than 0.05 were
considered statistically signiﬁcant.
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